Additional Information About Source of Study Drug and Typographical Error in Supplement

In the Original Investigation, “Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities: The I-TECH Randomized Clinical Trial,”¹ published online first in the February 18, 2022, issue of JAMA Internal Medicine, the following has been requested by the authors to be included in the beginning of the Methods, Intervention section: “The ivermectin used in the study was manufactured by Maxford Healthcare, a WHO good manufacturing practices certified pharmaceutical company in India where ivermectin is a registered product. At the time of the study, no ivermectin for patient use was registered in Malaysia. Hence, we imported and used the products as off-label for the purpose of this clinical trial with a conditional approval by our National Pharmaceutical Regulatory Agency.” In addition, there was a missing minus sign in a number reported in eTable 1 in Supplement 2. The article and Supplement 2 have been corrected online.